Choongwae to transfer Imiphenem technology to Sandoz.

Published: 2006-04-28 06:57:00

Updated: 2006-04-28 06:57:00

Imiphenem, a high value added antibiotic technology developed by a genuine Korean research team of Choongwae, seems to transfer to Sandoz, a subsidiary of Novartis and the 2nd largest generic drug company in the world.

The Imiphenem antibiotic technology was transferred to Sandoz at 9 p.m. on ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK